Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease

Nathalie Esser, Nicolas Paquot, André J. Scheen

Research output: Contribution to journalReview articlepeer-review

174 Scopus citations


Introduction: There is a growing body of evidence to suggest that chronic silent inflammation is a key feature in abdominal obesity, metabolic syndrome, type 2 diabetes (T2DM) and cardiovascular disease (CVD). These observations suggest that pharmacological strategies, which reduce inflammation, may be therapeutically useful in treating obesity, type 2 diabetes and associated CVD.Area covered: The article covers novel strategies, using either small molecules or monoclonal antibodies. These strategies include: approaches targeting IKK-b-NF-kB (salicylates, salsalate), TNF-α (etanercept, infliximab, adalimumab), IL-1β (anakinra, canakinumab) and IL-6 (tocilizumab), AMP-activated protein kinase activators, sirtuin-1 activators, mammalian target of rapamycin inhibitors and C-C motif chemokine receptor 2 antagonists.Expert opinion: The available data supports the concept that targeting inflammation improves insulin sensitivity and β-cell function; it also ameliorates glucose control in insulin-resistant patients with inflammatory rheumatoid diseases as well in patients with metabolic syndrome or T2DM. Although promising, the observed metabolic effects remain rather modest in most clinical trials. The potential use of combined anti-inflammatory agents targeting both insulin resistance and insulin secretion appears appealing but remains unexplored. Large-scale prospective clinical trials are underway to investigate the safety and efficacy of different anti-inflammatory drugs. Further evidence is needed to support the concept that targeting inflammation pathways may represent a valuable option to tackle the cardiometabolic complications of obesity.

Original languageEnglish
Pages (from-to)283-307
Number of pages25
JournalExpert Opinion on Investigational Drugs
Issue number3
StatePublished - Mar 2015
Externally publishedYes


  • Cardiovascular disease
  • IL-1
  • Inflammation
  • Insulin resistance
  • Salsalate
  • TNF-α
  • Type 2 diabetes mellitus


Dive into the research topics of 'Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease'. Together they form a unique fingerprint.

Cite this